StreetAlpha.app
Home › Stocks › CAI

Caris Life Sciences, Inc. (CAI)

Healthcare
$19.94
▼ −5.05%
LAST CLOSE · NOV 17

Caris Life Sciences provides cancer molecular profiling tests and related data services for doctors, researchers and drug developers. It last closed at $19.94 on Nov 17, down 5.05% on the day. The average 12-month price target from 6 analysts is $32.00 (+60.5% from the last close), with a high of $38.00 and a low of $25.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (3 buy, 3 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in CAI, 0% of them bullish and 100% bearish. In the past 30 days there were 2 dark pool prints totaling $6.1M, the largest $5.2M.

AI Auto Pilots
Is CAI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.0B
+61.5% vs a year ago
Net income
$96.1M
9.2% margin
EPS (diluted)
$1.66
Free cash flow
$28.9M
2.8% margin
Valuation
Market cap
$5.7B
286.8M shares
P/E
12.0
Price over 12 month EPS
Price to sales
5.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Debt
$393.0M
At Sep 30
Shareholder equity
$639.5M
Buybacks
$31.5M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $306.1M$306.1MFY2023FY2024: $412.3M$412.3MFY2024FY2025: $812.0M$812.0MFY2025

From CAI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
6firms
3 Buy3 Hold0 Sell
Each firm's latest rating on CAI in the past 90 days
Average 12-month target
$32.00
▲ 60.5% upside

Based on 6 analysts who set a price target on CAI in the past 90 days. The average target is $32.00, with a high of $38.00 and a low of $25.00, compared with the last close of $19.94.

Low $25.00Avg $32.00High $38.00
Blue marker: last close $19.94
Highest target$38.00
Average target$32.00
Lowest target$25.00
Latest rating changes
Piper SandlerTarget raised
Nov 10Hold$21 → $25
CitigroupMaintained
Nov 6Buy$36
TD CowenTarget raised
Nov 5Buy$36 → $38
Canaccord GenuityMaintained
Oct 19Hold$30
JP MorganMaintained
Oct 14Buy$35
DateFirmActionRatingPrice target
Nov 10Piper SandlerTarget raisedHold$21 → $25
Nov 6CitigroupMaintainedBuy$36
Nov 5TD CowenTarget raisedBuy$36 → $38
Oct 19Canaccord GenuityMaintainedHold$30
Oct 14JP MorganMaintainedBuy$35
Loading…

Technical Analysis

CAI · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 45% below its 20 day and 46% below its 50 day average. It is 8% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot S1 at $19.21, and the nearest resistance the swing high (Jun 26) at $19.97.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 10.8%/day
Key levels
$36.5052 week high+83.0%
$29.2150 day average+46.5%
$29.0020 day average+45.4%
$24.66100 day average+23.7%
$21.60200 day average+8.3%
$21.16Pivot R1+6.1%
$20.43Pivot+2.5%
$19.97Swing high (Jun 26)+0.2%
$19.94Last close
$19.21Pivot S1−3.7%
$17.50Swing low (Jun 30)−12.2%
$14.1952 week low−28.8%
Indicators
RSI (14)25.39Oversold below 30Oversold
MACD-2.33Below its signal lineBearish
Stochastic1.7Near the bottom of its rangeOversold
ADX (14)38.9Trending down
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-125.2Oversold below −100, overbought above 100Oversold
Rate of change−39.3%Change over 10 sessionsBearish
ATR (14)$2.16Typical daily range, 10.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CAI

What happened before

See how CAI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Oct 15 – Oct 15
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$6.1M
Largest print
$5.2M
Loading…

CAI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲229 buying vs 109 selling
  • ●Held by funds +0.3 pts
  • ▲Funds holding +80
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding329249+32.1%
In funds' top 1056−16.7%
Held by funds54.1%53.8%+0.3 pts
New / increased121 / 10868 / 105+32.4%
Reduced / sold out69 / 4048 / 24+51.4%
Put/call ratio0.250.64−60.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CAI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAI is in one of them and how their past CAI trades turned out.

CAI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CAI in an article yet. Here's the latest on the wider market.

About Caris Life Sciences

Caris Life Sciences, based in Irving, Texas, offers molecular profiling tests that analyze tumor tissue and blood samples to help guide cancer care. Its tests combine gene sequencing with artificial intelligence analysis, and it also sells data and bioinformatics services. Its customers include physicians and clinical labs, academic cancer research centers, and biopharma companies developing new drugs. The company focuses mainly on oncology.

Headquarters
Irving, TX